CMS issued the industry-wide ratings the next month. Among large insurers, UnitedHealthcare experienced one of the most ...

The U.S. Centers for Medicare and Medicaid Services on Friday said it would not appeal a court order that it recalculate the ...

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by ...

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...

The Centers for Medicare & Medicaid Services has changed course on plans to appeal a court ruling that determined it must ...

UnitedHealth (UNH) stock in focus as Medicare withdraws appeal over an unfavorable ruling related to the company's 2025-Star ...

The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing ...

In November, a federal judge ordered CMS to recalculate UnitedHealthcare's Medicare Advantage Star Ratings for the 2025 plan ...

Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.

The U.S. health agency, the Centers for Medicare & Medicaid Services (CMS), announced Tuesday that it will appeal a November 2024 ruling to the Fifth Circuit Court of Appeals. What Happened: In ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

The Biden administration’s last MA rule is a boon for insurers, though it remains to be seen how the incoming Trump ...